Literature DB >> 17022069

Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy.

Alfred E Slonim1, Linda Bulone, Teresia Goldberg, Jennifer Minikes, Efrat Slonim, Joseph Galanko, Frank Martiniuk.   

Abstract

Adult-onset acid maltase deficiency is an inherited lysosomal skeletal-muscle disease characterized by progressive myopathy and respiratory failure, for which there is no known therapy. In an uncontrolled, prospective study, we evaluated whether adherence to high-protein and low-carbohydrate nutrition and exercise therapy (NET) can slow the progressive deterioration of muscle function in this disease. Thirty-four patients have been treated with NET for periods of 2-10 years (mean 4.5 +/- 2.5). Pre-NET rate of muscle function deterioration, as measured by the Walton scale, was compared to post-NET rate. Twenty-six patients were deemed to be consistently compliant with NET. Difference between pre-NET slope of muscle function deterioration to that of post-NET slope in compliant patients was -0.29 (95% CI -0.19, 0.39) (P < 0.0001). We conclude that compliance with NET can slow deterioration of muscle function and improve the natural history of adult-onset acid maltase deficiency. Muscle Nerve, 2006.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17022069     DOI: 10.1002/mus.20665

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  38 in total

1.  Therapeutic advances in the management of Pompe disease and other metabolic myopathies.

Authors:  Corrado Angelini; Anna Chiara Nascimbeni; Claudio Semplicini
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

Review 2.  Enzyme replacement therapy for Pompe disease.

Authors:  Corrado Angelini; Claudio Semplicini
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

Review 3.  [Diagnosis and therapy of late onset Pompe disease].

Authors:  A Schüller; C Kornblum; M Deschauer; M Vorgerd; B Schrank; E Mengel; Z Lukacs; D Gläser; P Young; U Plöckinger; B Schoser
Journal:  Nervenarzt       Date:  2013-12       Impact factor: 1.214

4.  Identification and Functional Characterization of GAA Mutations in Colombian Patients Affected by Pompe Disease.

Authors:  Mónica Yasmín Niño; Heidi Eliana Mateus; Dora Janeth Fonseca; Marian A Kroos; Sandra Yaneth Ospina; Juan Fernando Mejía; Jesús Alfredo Uribe; Arnold J J Reuser; Paul Laissue
Journal:  JIMD Rep       Date:  2012-04-19

Review 5.  Nutrition and exercise in Pompe disease.

Authors:  Mark A Tarnopolsky; Mats I Nilsson
Journal:  Ann Transl Med       Date:  2019-07

6.  Therapeutic Benefit of Autophagy Modulation in Pompe Disease.

Authors:  Jeong-A Lim; Baodong Sun; Rosa Puertollano; Nina Raben
Journal:  Mol Ther       Date:  2018-05-03       Impact factor: 11.454

7.  Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency.

Authors:  Andrea Vianello; Claudio Semplicini; Luciana Paladini; Alessandra Concas; Sabrina Ravaglia; Serenella Servidei; Antonio Toscano; Tiziana Mongini; Corrado Angelini; Elena Pegoraro
Journal:  Lung       Date:  2013-07-10       Impact factor: 2.584

8.  Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy.

Authors:  A Broomfield; J Fletcher; J Davison; N Finnegan; M Fenton; A Chikermane; C Beesley; K Harvey; E Cullen; C Stewart; S Santra; S Vijay; M Champion; L Abulhoul; S Grunewald; A Chakrapani; M A Cleary; S A Jones; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2015-10-26       Impact factor: 4.982

9.  Recent developments, utilization, and spending trends for pompe disease therapies.

Authors:  Jing Guo; Christina M L Kelton; Jeff J Guo
Journal:  Am Health Drug Benefits       Date:  2012-05

10.  Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease.

Authors:  Michael Beck
Journal:  Ther Clin Risk Manag       Date:  2009-09-24       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.